Individual patients may have substantial differences in their eGFRcr and eGFRcys for estimating kidney function, which has prognostic implications.

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Ascendis Pharma (ASND) announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults ...

National implementation of a race-neutral eGFR equation contributed to more modifications and higher kidney transplantation rates for Black candidates, according to study data published in the Journal ...

In both trials, TransCon PTH was generally well tolerated, with no new safety signals identified. Most treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1 or 2) and no patients ...

Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech. AstraZeneca is also ...